{
  "first_published_at": "2008-10-01", 
  "original_url": "http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON087807", 
  "title": "Ergot-derived dopamine agonists: risk of fibrotic reactions in chronic endocrine uses", 
  "tags": "{\"parsed_therapeutic\": [\"endocrinology-diabetology-metabolism\", \"neurology\"], \"Audience:\": [\"Primary care\", \"Secondary care\"], \"Therapeutic area:\": [\"Endocrinology, diabetology and metabolism\", \"Neurology\"]}", 
  "_document_number": 279, 
  "label": null, 
  "icon": "http://www.mhra.gov.uk/home/images/MHRALook/img/dsu/adverse_icon.png", 
  "therapeutic_area": [
    "endocrinology-diabetology-metabolism", 
    "neurology"
  ], 
  "raw_html": "<div id=\"dsuArticleContent\">\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\t<h1><a name=\"maincontent\" id=\"maincontent\"></a>Ergot-derived dopamine agonists: risk of fibrotic reactions in chronic endocrine uses</h1>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<span class=\"ref\">Article date: October 2008</span> \r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t<!---->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<div id=\"dsuSynopsis\" class=\"yellow\">\r\n\t\t\t\t\t\t\t\t\t<div class=\"dsuArticlePadding\">\r\n\t\t\t\t\t\t\t\t\t<span id=\"dsuSynopsisTitle\"><b>Summary</b></span>\t\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\t<br>Chronic use of ergot-derived dopamine agonists is associated with a risk of fibrosis, particularly cardiac fibrosis. Cardiac valvulopathy should be excluded by echocardiography before treatment with cabergoline or bromocriptine. Patients should be monitored during treatment as outlined below<br>\t\r\n\t\t\t\t\t\t\t\t\t</div>         \t\t\r\n\t\t\t\t\t\t\t\t\t<div id=\"dsuSynopsisCut\">\r\n\t\t\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t<!--<p><a href=\"http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2009/11/WC500015110.pdf\" target=\"_blank\">The European Medicines Agency has recommended</a> new warnings and contraindications for ergot-derived dopamine agonists as a result of the risk of fibrosis, particularly cardiac fibrosis, associated with chronic use. The risk of cardiac fibrosis is higher with cabergoline and pergolide than with the other ergot-derived dopamine agonists.</p><p>Cabergoline, pergolide, and bromocriptine are indicated for the treatment of Parkinson&rsquo;s disease. Key advice on new warnings, contraindications, dose, and side-effects has previously been provided for this indication (see <a href=\"http://www.mhra.gov.uk/Publications/Safetyguidance/DrugSafetyUpdate/CON020566\" target=\"_blank\">Drug Safety Update July 2008</a>, p9).</p><p>Cabergoline (brand leader Dostinex) is used in hyperprolactinaemia. The recommended initial Dostinex dose for this indication is 0&middot;5 mg a week, given in one or two doses a week and titrated according to prolactin levels; therapeutic dose is usually 1 mg a week. Bromocriptine (brand leader Parlodel) is indicated for chronic endocrine disorders such as hyperprolactinaemia and acromegaly. For dosing information, refer to the <a href=\"http://emc.medicines.org.uk/\" target=\"_blank\">Summaries of Product Characteristics</a>. This new advice applies only to treatment of chronic endocrine disorders with these agents&mdash;it does not apply to the inhibition of lactation.</p><div class=\"dull_highlight\">\r\n\t\t\t<p><strong>Advice for healthcare professionals:</strong></p>\r\n\t\t\t<p><strong><em>Cabergoline and bromocriptine</em></strong></p>\r\n\t\t\t<ul>\r\n\t\t\t\t<li>Exclude cardiac valvulopathy as determined by echocardiography before treatment</li>\r\n\t\t\t\t<li>Monitor patients for signs or symptoms of pleuropulmonary disease (eg, dyspnoea, shortness of breath, persistent cough, or chest pain) and retroperitoneal disorders during treatment. Renal insufficiency or ureteral or abdominal vascular obstruction might occur, with pain in the loin or flank and leg oedema. Abdominal masses or tenderness could suggest retroperitoneal fibrosis</li>\r\n\t\t\t</ul>\r\n\t\t\t<p><strong><em>Cabergoline</em></strong></p>\r\n\t\t\t<ul>\r\n\t\t\t\t<li>Monitor patients for signs of cardiac fibrosis during treatment</li>\r\n\t\t\t\t<li>Echocardiography should be done within 3&ndash;6 months of starting treatment and subsequently at 6&ndash;12-month intervals</li>\r\n\t\t\t\t<li>Stop treatment if echocardiography shows new or worsened valvular regurgitation, valvular restriction, or valve leaflet thickening</li>\r\n\t\t\t\t<li>Pregnancy should be excluded before administration of cabergoline</li>\r\n\t\t\t\t<li>Women who are planning pregnancy should stop taking cabergoline 1 month before they try to conceive</li>\r\n\t\t\t</ul></div><p>&nbsp;</p><p>&nbsp;</p><p><em>Article citation: Drug Safety Update Oct 2008, vol 2 issue 3: 2.</em></p>-->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_BEGIN_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t\t<!-- call include to dynamically insert alt attributes into image tags within a wysiwyg element -->\r\n<!-- get a reference to the wysiwyg content -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n\t<p><a href=\"http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2009/11/WC500015110.pdf\" target=\"_blank\">The European Medicines Agency has recommended</a> new warnings and contraindications for ergot-derived dopamine agonists as a result of the risk of fibrosis, particularly cardiac fibrosis, associated with chronic use. The risk of cardiac fibrosis is higher with cabergoline and pergolide than with the other ergot-derived dopamine agonists.</p><p>Cabergoline, pergolide, and bromocriptine are indicated for the treatment of Parkinson&#8217;s disease. Key advice on new warnings, contraindications, dose, and side-effects has previously been provided for this indication (see <a href=\"http://www.mhra.gov.uk/Publications/Safetyguidance/DrugSafetyUpdate/CON020566\" target=\"_blank\">Drug Safety Update July 2008</a>, p9).</p><p>Cabergoline (brand leader Dostinex) is used in hyperprolactinaemia. The recommended initial Dostinex dose for this indication is 0&#183;5 mg a week, given in one or two doses a week and titrated according to prolactin levels; therapeutic dose is usually 1 mg a week. Bromocriptine (brand leader Parlodel) is indicated for chronic endocrine disorders such as hyperprolactinaemia and acromegaly. For dosing information, refer to the <a href=\"http://emc.medicines.org.uk/\" target=\"_blank\">Summaries of Product Characteristics</a>. This new advice applies only to treatment of chronic endocrine disorders with these agents&#8212;it does not apply to the inhibition of lactation.</p><div class=\"dull_highlight\">\r\n\t\t\t<p><strong>Advice for healthcare professionals:</strong></p>\r\n\t\t\t<p><strong><em>Cabergoline and bromocriptine</em></strong></p>\r\n\t\t\t<ul>\r\n\t\t\t\t<li>Exclude cardiac valvulopathy as determined by echocardiography before treatment</li>\r\n\t\t\t\t<li>Monitor patients for signs or symptoms of pleuropulmonary disease (eg, dyspnoea, shortness of breath, persistent cough, or chest pain) and retroperitoneal disorders during treatment. Renal insufficiency or ureteral or abdominal vascular obstruction might occur, with pain in the loin or flank and leg oedema. Abdominal masses or tenderness could suggest retroperitoneal fibrosis</li>\r\n\t\t\t</ul>\r\n\t\t\t<p><strong><em>Cabergoline</em></strong></p>\r\n\t\t\t<ul>\r\n\t\t\t\t<li>Monitor patients for signs of cardiac fibrosis during treatment</li>\r\n\t\t\t\t<li>Echocardiography should be done within 3&#8211;6 months of starting treatment and subsequently at 6&#8211;12-month intervals</li>\r\n\t\t\t\t<li>Stop treatment if echocardiography shows new or worsened valvular regurgitation, valvular restriction, or valve leaflet thickening</li>\r\n\t\t\t\t<li>Pregnancy should be excluded before administration of cabergoline</li>\r\n\t\t\t\t<li>Women who are planning pregnancy should stop taking cabergoline 1 month before they try to conceive</li>\r\n\t\t\t</ul></div><p>&#160;</p><p>&#160;</p><p><em>Article citation: Drug Safety Update Oct 2008, vol 2 issue 3: 2.</em></p>\r\n\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_END_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t", 
  "date_of_article": "2008-10-01", 
  "date_last_modified": "2010-09-22", 
  "_assets": [], 
  "_item_id": 279, 
  "summary": "Chronic use of ergot-derived dopamine agonists is associated with a risk of fibrosis, particularly cardiac fibrosis. Cardiac valvulopathy should be excluded by echocardiography before treatment with cabergoline or bromocriptine. Patients should be monitored during treatment as outlined below", 
  "body": "Article date: October 2008\n\n[The European Medicines Agency has recommended](http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2009/11/WC500015110.pdf) new warnings and contraindications for ergot-derived dopamine agonists as a result of the risk of fibrosis, particularly cardiac fibrosis, associated with chronic use. The risk of cardiac fibrosis is higher with cabergoline and pergolide than with the other ergot-derived dopamine agonists.\n\nCabergoline, pergolide, and bromocriptine are indicated for the treatment of Parkinson’s disease. Key advice on new warnings, contraindications, dose, and side-effects has previously been provided for this indication (see [Drug Safety Update July 2008](http://www.mhra.gov.uk/Publications/Safetyguidance/DrugSafetyUpdate/CON020566), p9).\n\nCabergoline (brand leader Dostinex) is used in hyperprolactinaemia. The recommended initial Dostinex dose for this indication is 0·5 mg a week, given in one or two doses a week and titrated according to prolactin levels; therapeutic dose is usually 1 mg a week. Bromocriptine (brand leader Parlodel) is indicated for chronic endocrine disorders such as hyperprolactinaemia and acromegaly. For dosing information, refer to the [Summaries of Product Characteristics](http://emc.medicines.org.uk/). This new advice applies only to treatment of chronic endocrine disorders with these agents—it does not apply to the inhibition of lactation.\n\nAdvice for healthcare professionals:\n\nCabergoline and bromocriptine  \n  \n  * Exclude cardiac valvulopathy as determined by echocardiography before treatment  \n  * Monitor patients for signs or symptoms of pleuropulmonary disease (eg, dyspnoea, shortness of breath, persistent cough, or chest pain) and retroperitoneal disorders during treatment. Renal insufficiency or ureteral or abdominal vascular obstruction might occur, with pain in the loin or flank and leg oedema. Abdominal masses or tenderness could suggest retroperitoneal fibrosis  \n  \nCabergoline  \n  \n  * Monitor patients for signs of cardiac fibrosis during treatment  \n  * Echocardiography should be done within 3–6 months of starting treatment and subsequently at 6–12-month intervals  \n  * Stop treatment if echocardiography shows new or worsened valvular regurgitation, valvular restriction, or valve leaflet thickening  \n  * Pregnancy should be excluded before administration of cabergoline  \n  * Women who are planning pregnancy should stop taking cabergoline 1 month before they try to conceive  \n  \n \n\n \n\nArticle citation: Drug Safety Update Oct 2008, vol 2 issue 3: 2.\n"
}